TY - JOUR
T1 - SARS-CoV-2 Omicron XBB.1 variant outbreak in a defined cohort
T2 - an epidemiological investigation incorporating longitudinal assessment of humoral response
AU - Margalit, Ili
AU - Weiss-Ottolenghi, Yael
AU - Panet, Einat
AU - Indenbaum, Victoria
AU - Zuckerman, Neta S.
AU - Joseph, Gili
AU - Peretz, Yovel
AU - Barda, Noam
AU - Lustig, Yaniv
AU - Regev-Yochay, Gili
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/11/1
Y1 - 2024/11/1
N2 - Background: We describe an epidemiological investigation of a SARS-CoV-2-XBB.1 outbreak among healthcare workers (HCWs) returning from a 5-days educational tour abroad. Methods: We prospectively followed participants for symptoms and sampled blood for neutralization assays of four SARS-CoV-2 variants (wild type, XBB, EG.5.1, and BA.2.86) at 1, 3, and 6 months after their return. When available, samples from the 3 months preceding the outbreak were also tested. We compared geometric mean titers (GMT) of neutralizing antibodies of infected versus uninfected HCWs and febrile versus afebrile infected HCWs. Results: Nineteen (10%) of 181 HCWs were infected, all had mild COVID-19, 90% (17/19) had symptoms, and 16% (3/19) reported fever. Infected individuals tended to have lower pre-exposure XBB-neutralizing antibody titers (GMT of 32 versus 107 ID50, P = 0.248). Neutralization against XBB and newer subvariants peaked at 3 months and was higher among infected individuals (GMT 702 versus 156 [P < 0.001], 558 versus 163 [P = 0.001], and 558 vs. 182 [P = 0.002], ID50 for XBB, EG.5.1., and BA.2.86, respectively). By six months, these differences were no longer observed. Fever was positively associated with XBB neutralization (GMT 3474 versus 485, ID50 P = 0.005). Conclusions: Recently infected individuals are protected from reinfection with newer subvariants. However, protection is likely short lived.
AB - Background: We describe an epidemiological investigation of a SARS-CoV-2-XBB.1 outbreak among healthcare workers (HCWs) returning from a 5-days educational tour abroad. Methods: We prospectively followed participants for symptoms and sampled blood for neutralization assays of four SARS-CoV-2 variants (wild type, XBB, EG.5.1, and BA.2.86) at 1, 3, and 6 months after their return. When available, samples from the 3 months preceding the outbreak were also tested. We compared geometric mean titers (GMT) of neutralizing antibodies of infected versus uninfected HCWs and febrile versus afebrile infected HCWs. Results: Nineteen (10%) of 181 HCWs were infected, all had mild COVID-19, 90% (17/19) had symptoms, and 16% (3/19) reported fever. Infected individuals tended to have lower pre-exposure XBB-neutralizing antibody titers (GMT of 32 versus 107 ID50, P = 0.248). Neutralization against XBB and newer subvariants peaked at 3 months and was higher among infected individuals (GMT 702 versus 156 [P < 0.001], 558 versus 163 [P = 0.001], and 558 vs. 182 [P = 0.002], ID50 for XBB, EG.5.1., and BA.2.86, respectively). By six months, these differences were no longer observed. Fever was positively associated with XBB neutralization (GMT 3474 versus 485, ID50 P = 0.005). Conclusions: Recently infected individuals are protected from reinfection with newer subvariants. However, protection is likely short lived.
KW - COVID-19
KW - Healthcare workers
KW - Infection control
KW - Virus neutralization
UR - http://www.scopus.com/inward/record.url?scp=85205482807&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2024.107240
DO - 10.1016/j.ijid.2024.107240
M3 - Article
C2 - 39270926
AN - SCOPUS:85205482807
SN - 1201-9712
VL - 148
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
M1 - 107240
ER -